Ophthalmology News

Ophthal

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Arevalo JF et al. – Short–term results suggest that IVT bevacizumab is well tolerated in patients with refractory pseudophakic CME. Treated eyes had a significant improvement in BCVA and decrease in macular thickness by OCT at 12 months.

Related Articles

The Course of Response To Focal/Grid Photocoagulation for Diabetic Macular Edema
Retina, 11/25/09    Relevance Score: 69%%

Macular microcirculation before and after vitrectomy for macular edema with branch retinal vein occlusion
Graefe's Archive for Clinical and Experimental Ophthalmology, 12/10/09    Relevance Score: 68%%

Intravitreal Combination of Triamcinolone Acetonide and Bevacizumab (Kenacort-Avastin) in Diffuse Diabetic Macular Edema
Seminars in Ophthalmology, 12/10/09    Relevance Score: 68%%

Phacoemulsification With Intravitreal Bevacizumab Injection in Diabetic Patients With Macular Edema and Cataract
Retina, 11/20/09    Relevance Score: 68%%

Pars plana vitrectomy with ILM peeling for macular edema secondary to retinal vein occlusion
European Journal of Ophthalmology, 11/13/09    Relevance Score: 68%%

Today in Clinical Pharmacology...keeping you current

Intravitreal Bevacizumab and Ranibizumab for Age-Related Macular Degeneration: A Multicenter, Retrospective Study
Ophthalmology, 12/15/09

Triamcinolone Acetonide Injection for Persistent Atypical Idiopathic Orbital Inflammation
Orbit - The International Journal on Orbital Disorders, Oculoplastic and Lacrimal Surgery, 12/11/09

Intravitreal Combination of Triamcinolone Acetonide and Bevacizumab (Kenacort-Avastin) in Diffuse Diabetic Macular Edema
Seminars in Ophthalmology, 12/10/09

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address